Resistance as a Design Constraint: Next-generation Chimeric Antigen Receptor Engineering Strategies and Emerging Frontiers in Cancer Immunotherapy

Chimeric antigen receptor (CAR) T-cell therapy has altered the treatment of several B-cell malignancies and multiple myeloma, yet a substantial proportion of treated patients relapse, and activity in solid tumours remains limited. The field has responded with an expanding repertoire of engineering strategies, including multi-antigen targeting, affinity and signalling redesign, logic-gated receptors, cytokine armouring, transcriptional and metabolic reprogramming, precise gene editing, allogeneic and in vivo generated products, and alternative effector cells. This review examines that repertoire critically, taking resistance rather than platform novelty as its organising principle. Literature was identified through structured searching of open scholarly databases and indexes, supplemented by targeted retrieval of foundational reports and by checking for corrections and retraction notices, with each included source verified for bibliographic identity and for its relationship to the claim it supports. Evidence was appraised against a four-level scheme distinguishing clinical demonstration of durability, clinical demonstration of activity, mechanistic demonstration in human material or immunocompetent models, and mechanistic plausibility alone. Three findings emerge. Resistance is not a single phenomenon but a set of mechanistically distinct failure modes, several of which were conflated in earlier accounts, and antigen density behaves as a continuous determinant rather than a binary presence or absence. Most next-generation strategies currently rest on level three or level four evidence, so the gap between mechanistic demonstration and demonstrated durability is wider than the volume of publication suggests. Strategies that intensify effector function tend to approach a shared toxicity and manufacturing ceiling, which constrains how far intensification can be pursued independently of delivery and access considerations. Unresolved questions concern the predictive value of pre-infusion product attributes, the durability of logic-gated and armoured designs in human disease, the long-term safety of multiplexed editing, and whether decentralised manufacturing can reconcile biological sophistication with equitable availability. Confidence in current conclusions about next-generation designs remains limited by short follow-up, small single-arm cohorts and uneven geographical representation of the evidence.

Authors

Institutions

Publication Details

Journal
Asian Journal of Research in Medical and Pharmaceutical Sciences
Published
2026-11-14
DOI
https://doi.org/10.9734/ajrimps/2026/v15i4437
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Resistance as a Design Constraint: Next-generation Chimeric Antigen Receptor Engineering Strategies and Emerging Frontiers in Cancer Immunotherapy

Sohel Shiakh, Hashim Mansori, Iqra Momin, Priyanka Sawant
Asian Journal of Research in Medical and Pharmaceutical Sciences
CAR-T cell therapy research
article

Resistance as a Design Constraint: Next-generation Chimeric Antigen Receptor Engineering Strategies and Emerging Frontiers in Cancer Immunotherapy

Sohel Shiakh, Hashim Mansori, Iqra Momin, Priyanka Sawant
article en

Abstract

Chimeric antigen receptor (CAR) T-cell therapy has altered the treatment of several B-cell malignancies and multiple myeloma, yet a substantial proportion of treated patients relapse, and activity in solid tumours remains limited. The field has responded with an expanding repertoire of engineering strategies, including multi-antigen targeting, affinity and signalling redesign, logic-gated receptors, cytokine armouring, transcriptional and metabolic reprogramming, precise gene editing, allogeneic and in vivo generated products, and alternative effector cells. This review examines that repertoire critically, taking resistance rather than platform novelty as its organising principle. Literature was identified through structured searching of open scholarly databases and indexes, supplemented by targeted retrieval of foundational reports and by checking for corrections and retraction notices, with each included source verified for bibliographic identity and for its relationship to the claim it supports. Evidence was appraised against a four-level scheme distinguishing clinical demonstration of durability, clinical demonstration of activity, mechanistic demonstration in human material or immunocompetent models, and mechanistic plausibility alone. Three findings emerge. Resistance is not a single phenomenon but a set of mechanistically distinct failure modes, several of which were conflated in earlier accounts, and antigen density behaves as a continuous determinant rather than a binary presence or absence. Most next-generation strategies currently rest on level three or level four evidence, so the gap between mechanistic demonstration and demonstrated durability is wider than the volume of publication suggests. Strategies that intensify effector function tend to approach a shared toxicity and manufacturing ceiling, which constrains how far intensification can be pursued independently of delivery and access considerations. Unresolved questions concern the predictive value of pre-infusion product attributes, the durability of logic-gated and armoured designs in human disease, the long-term safety of multiplexed editing, and whether decentralised manufacturing can reconcile biological sophistication with equitable availability. Confidence in current conclusions about next-generation designs remains limited by short follow-up, small single-arm cohorts and uneven geographical representation of the evidence.

Asian Journal of Research in Medical and Pharmaceutical SciencesVol. 15(4)
MSD (India) (IN)
CAR-T cell therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon